| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 22 | 2025 | 498 | 4.340 |
Why?
|
| Influenza, Human | 21 | 2025 | 699 | 3.680 |
Why?
|
| Immunogenicity, Vaccine | 17 | 2025 | 114 | 3.070 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 8 | 2025 | 30 | 3.020 |
Why?
|
| Antibodies, Viral | 33 | 2025 | 1203 | 2.410 |
Why?
|
| Immunization, Secondary | 12 | 2025 | 113 | 1.990 |
Why?
|
| Vaccines | 6 | 2023 | 382 | 1.760 |
Why?
|
| Adjuvants, Immunologic | 14 | 2025 | 391 | 1.540 |
Why?
|
| Vaccines, Inactivated | 12 | 2025 | 148 | 1.330 |
Why?
|
| Antibodies, Neutralizing | 21 | 2025 | 501 | 1.290 |
Why?
|
| Influenza A Virus, H7N7 Subtype | 2 | 2020 | 11 | 1.270 |
Why?
|
| HIV Infections | 10 | 2025 | 2035 | 1.220 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 5 | 2021 | 61 | 1.160 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 3 | 2025 | 62 | 1.070 |
Why?
|
| Respiratory Tract Infections | 3 | 2026 | 291 | 1.050 |
Why?
|
| Polysorbates | 8 | 2025 | 27 | 0.990 |
Why?
|
| Hemagglutination Inhibition Tests | 15 | 2025 | 114 | 0.950 |
Why?
|
| Mycobacterium tuberculosis | 6 | 2013 | 413 | 0.950 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2025 | 13 | 0.920 |
Why?
|
| Histoplasmosis | 1 | 2025 | 55 | 0.890 |
Why?
|
| Neuraminidase | 1 | 2025 | 39 | 0.890 |
Why?
|
| Adult | 60 | 2026 | 31547 | 0.850 |
Why?
|
| Zika Virus Infection | 5 | 2024 | 175 | 0.830 |
Why?
|
| Tuberculosis | 5 | 2014 | 554 | 0.820 |
Why?
|
| Humans | 105 | 2026 | 131985 | 0.770 |
Why?
|
| Squalene | 7 | 2025 | 25 | 0.760 |
Why?
|
| Bacteremia | 2 | 2019 | 428 | 0.760 |
Why?
|
| Vaccination | 15 | 2025 | 1018 | 0.740 |
Why?
|
| Zika Virus | 5 | 2024 | 151 | 0.710 |
Why?
|
| Microcephaly | 2 | 2024 | 351 | 0.700 |
Why?
|
| Middle Aged | 45 | 2026 | 28976 | 0.690 |
Why?
|
| Influenza in Birds | 1 | 2020 | 28 | 0.650 |
Why?
|
| Young Adult | 26 | 2025 | 9952 | 0.630 |
Why?
|
| Clostridium septicum | 1 | 2019 | 2 | 0.620 |
Why?
|
| Liver Abscess, Pyogenic | 1 | 2019 | 3 | 0.620 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 201 | 0.610 |
Why?
|
| Antitubercular Agents | 4 | 2013 | 264 | 0.600 |
Why?
|
| Male | 59 | 2026 | 64910 | 0.600 |
Why?
|
| Population Surveillance | 5 | 2013 | 416 | 0.590 |
Why?
|
| Encephalitis | 1 | 2019 | 118 | 0.580 |
Why?
|
| Viral Load | 3 | 2024 | 404 | 0.570 |
Why?
|
| Hemagglutinins | 2 | 2021 | 25 | 0.550 |
Why?
|
| Acanthamoeba | 1 | 2017 | 10 | 0.540 |
Why?
|
| Amebiasis | 1 | 2017 | 11 | 0.540 |
Why?
|
| Antiprotozoal Agents | 1 | 2017 | 41 | 0.530 |
Why?
|
| Female | 58 | 2026 | 70623 | 0.520 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 441 | 0.510 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 262 | 0.500 |
Why?
|
| Anthrax Vaccines | 5 | 2016 | 26 | 0.490 |
Why?
|
| Clostridium Infections | 1 | 2019 | 249 | 0.480 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2011 | 382 | 0.480 |
Why?
|
| Spike Glycoprotein, Coronavirus | 5 | 2024 | 205 | 0.480 |
Why?
|
| Immunization Schedule | 6 | 2024 | 107 | 0.470 |
Why?
|
| Adolescent | 31 | 2025 | 20535 | 0.460 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 316 | 0.460 |
Why?
|
| RNA, Viral | 3 | 2024 | 562 | 0.460 |
Why?
|
| Double-Blind Method | 16 | 2025 | 1658 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2025 | 1246 | 0.450 |
Why?
|
| Francisella tularensis | 2 | 2017 | 16 | 0.440 |
Why?
|
| Bacterial Vaccines | 2 | 2017 | 103 | 0.430 |
Why?
|
| Seizures | 1 | 2019 | 893 | 0.430 |
Why?
|
| Guatemala | 6 | 2024 | 64 | 0.430 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2013 | 188 | 0.410 |
Why?
|
| Disease Outbreaks | 2 | 2008 | 329 | 0.410 |
Why?
|
| Viral Vaccines | 3 | 2024 | 343 | 0.400 |
Why?
|
| Adenosine Monophosphate | 2 | 2024 | 42 | 0.390 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2005 | 229 | 0.380 |
Why?
|
| Alanine | 2 | 2024 | 159 | 0.370 |
Why?
|
| Antigens, Viral | 2 | 2024 | 437 | 0.370 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 1015 | 0.370 |
Why?
|
| Urban Population | 1 | 2013 | 243 | 0.360 |
Why?
|
| Antibodies, Bacterial | 7 | 2017 | 406 | 0.360 |
Why?
|
| Dengue | 2 | 2024 | 122 | 0.360 |
Why?
|
| Aged | 21 | 2025 | 21415 | 0.350 |
Why?
|
| Aza Compounds | 1 | 2011 | 15 | 0.350 |
Why?
|
| Immunoglobulin G | 10 | 2025 | 806 | 0.340 |
Why?
|
| Malaria Vaccines | 1 | 2010 | 24 | 0.330 |
Why?
|
| Quinolines | 1 | 2011 | 120 | 0.330 |
Why?
|
| Antigens, Protozoan | 1 | 2010 | 78 | 0.320 |
Why?
|
| Malaria, Falciparum | 1 | 2010 | 70 | 0.320 |
Why?
|
| Injections, Intramuscular | 10 | 2025 | 196 | 0.320 |
Why?
|
| Orthomyxoviridae | 2 | 2011 | 52 | 0.310 |
Why?
|
| RNA, Messenger | 4 | 2023 | 2674 | 0.310 |
Why?
|
| Case-Control Studies | 6 | 2025 | 3410 | 0.310 |
Why?
|
| Protozoan Proteins | 1 | 2010 | 133 | 0.300 |
Why?
|
| Injections, Intradermal | 4 | 2025 | 31 | 0.300 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 1381 | 0.290 |
Why?
|
| Anthrax | 3 | 2014 | 31 | 0.290 |
Why?
|
| Child Development | 2 | 2021 | 271 | 0.280 |
Why?
|
| Treatment Outcome | 11 | 2025 | 13019 | 0.280 |
Why?
|
| Tuberculosis, Central Nervous System | 1 | 2007 | 11 | 0.270 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2024 | 83 | 0.270 |
Why?
|
| Brain | 1 | 2019 | 3175 | 0.270 |
Why?
|
| Antiviral Agents | 2 | 2024 | 822 | 0.260 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2024 | 827 | 0.260 |
Why?
|
| Vaccines, Synthetic | 6 | 2022 | 322 | 0.250 |
Why?
|
| Organophosphonates | 1 | 2006 | 21 | 0.250 |
Why?
|
| Smallpox Vaccine | 2 | 2017 | 38 | 0.240 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2006 | 37 | 0.240 |
Why?
|
| Polymorphism, Genetic | 3 | 2004 | 803 | 0.240 |
Why?
|
| Texas | 8 | 2013 | 3628 | 0.230 |
Why?
|
| Immunity, Mucosal | 1 | 2025 | 94 | 0.230 |
Why?
|
| Placebos | 5 | 2016 | 234 | 0.230 |
Why?
|
| Histoplasma | 1 | 2025 | 37 | 0.230 |
Why?
|
| Administration, Mucosal | 1 | 2025 | 1 | 0.230 |
Why?
|
| Adenine | 1 | 2006 | 120 | 0.230 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2005 | 76 | 0.230 |
Why?
|
| Infant | 9 | 2024 | 13047 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2017 | 233 | 0.220 |
Why?
|
| Patient Acuity | 2 | 2021 | 67 | 0.220 |
Why?
|
| Clinical Trials as Topic | 5 | 2022 | 1161 | 0.220 |
Why?
|
| Azetidines | 2 | 2022 | 64 | 0.210 |
Why?
|
| Mannose-Binding Lectin | 1 | 2004 | 5 | 0.210 |
Why?
|
| Creatinine | 1 | 2006 | 412 | 0.210 |
Why?
|
| Single-Blind Method | 2 | 2021 | 243 | 0.210 |
Why?
|
| Purines | 2 | 2022 | 113 | 0.210 |
Why?
|
| Dengue Virus | 2 | 2024 | 132 | 0.210 |
Why?
|
| Area Under Curve | 1 | 2024 | 321 | 0.210 |
Why?
|
| Nasopharynx | 1 | 2024 | 88 | 0.210 |
Why?
|
| Research Design | 2 | 2025 | 742 | 0.200 |
Why?
|
| Schistosomiasis mansoni | 1 | 2023 | 24 | 0.200 |
Why?
|
| Water Microbiology | 1 | 2002 | 30 | 0.190 |
Why?
|
| Water Supply | 1 | 2002 | 26 | 0.190 |
Why?
|
| Incidence | 4 | 2021 | 3378 | 0.190 |
Why?
|
| Mycobacterium | 1 | 2002 | 30 | 0.190 |
Why?
|
| Azithromycin | 1 | 2022 | 43 | 0.190 |
Why?
|
| Vancomycin | 1 | 2024 | 222 | 0.190 |
Why?
|
| Mycobacterium Infections | 1 | 2002 | 32 | 0.190 |
Why?
|
| Aedes | 1 | 2023 | 104 | 0.190 |
Why?
|
| Antifungal Agents | 1 | 2025 | 312 | 0.190 |
Why?
|
| Vomiting | 1 | 2023 | 108 | 0.190 |
Why?
|
| Cough | 1 | 2023 | 96 | 0.190 |
Why?
|
| Pandemics | 4 | 2023 | 1183 | 0.190 |
Why?
|
| Sulfonamides | 2 | 2022 | 285 | 0.190 |
Why?
|
| Injections, Subcutaneous | 5 | 2017 | 127 | 0.190 |
Why?
|
| Growth Disorders | 1 | 2023 | 191 | 0.180 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2021 | 13 | 0.180 |
Why?
|
| Follow-Up Studies | 5 | 2026 | 5412 | 0.180 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 63 | 0.180 |
Why?
|
| Pyrazoles | 2 | 2022 | 332 | 0.180 |
Why?
|
| Healthy Volunteers | 4 | 2025 | 152 | 0.180 |
Why?
|
| Vaccines, Attenuated | 3 | 2017 | 176 | 0.180 |
Why?
|
| Diarrhea | 1 | 2023 | 330 | 0.170 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2021 | 45 | 0.170 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2024 | 466 | 0.170 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 7100 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 822 | 0.170 |
Why?
|
| DNA, Bacterial | 3 | 2011 | 494 | 0.170 |
Why?
|
| Emigration and Immigration | 1 | 2000 | 83 | 0.170 |
Why?
|
| United States | 9 | 2024 | 11653 | 0.160 |
Why?
|
| Occupational Health | 1 | 2020 | 47 | 0.160 |
Why?
|
| Critical Illness | 1 | 2024 | 618 | 0.160 |
Why?
|
| Mycobacterium avium Complex | 2 | 2021 | 20 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2024 | 6569 | 0.160 |
Why?
|
| Birds | 1 | 2020 | 86 | 0.160 |
Why?
|
| Lipid A | 1 | 2019 | 24 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 178 | 0.160 |
Why?
|
| Motor Skills | 1 | 2020 | 82 | 0.160 |
Why?
|
| Language Tests | 1 | 2019 | 26 | 0.160 |
Why?
|
| Cytokines | 3 | 2020 | 1359 | 0.150 |
Why?
|
| Glucosides | 1 | 2019 | 48 | 0.150 |
Why?
|
| Schistosomiasis | 1 | 2019 | 54 | 0.150 |
Why?
|
| Antibodies, Helminth | 1 | 2019 | 125 | 0.150 |
Why?
|
| Cross Infection | 1 | 2002 | 342 | 0.150 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2024 | 560 | 0.150 |
Why?
|
| Body Fluids | 1 | 2019 | 47 | 0.150 |
Why?
|
| Acute Kidney Injury | 1 | 2006 | 672 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 94 | 0.140 |
Why?
|
| Workflow | 1 | 2019 | 135 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2019 | 1284 | 0.140 |
Why?
|
| Language Development Disorders | 1 | 2019 | 179 | 0.140 |
Why?
|
| Tularemia | 1 | 2017 | 13 | 0.140 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 496 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 1028 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 2554 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2021 | 408 | 0.130 |
Why?
|
| Vaccinia virus | 1 | 2017 | 49 | 0.130 |
Why?
|
| Influenza B virus | 2 | 2023 | 100 | 0.130 |
Why?
|
| Child, Preschool | 8 | 2024 | 14732 | 0.130 |
Why?
|
| Immunoglobulin A | 2 | 2025 | 219 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 299 | 0.130 |
Why?
|
| Learning | 1 | 2020 | 370 | 0.120 |
Why?
|
| Child | 7 | 2024 | 25762 | 0.120 |
Why?
|
| Drug Carriers | 1 | 2017 | 119 | 0.120 |
Why?
|
| Pneumococcal Vaccines | 1 | 2017 | 172 | 0.120 |
Why?
|
| Caregivers | 1 | 2021 | 588 | 0.120 |
Why?
|
| Coccidioidomycosis | 1 | 2015 | 11 | 0.120 |
Why?
|
| Pneumococcal Infections | 1 | 2017 | 277 | 0.120 |
Why?
|
| Cholecystitis | 1 | 2015 | 21 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2022 | 5166 | 0.120 |
Why?
|
| Streptococcus pneumoniae | 1 | 2017 | 381 | 0.120 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2015 | 24 | 0.120 |
Why?
|
| Health Personnel | 1 | 2020 | 543 | 0.110 |
Why?
|
| Biomarkers | 1 | 2024 | 3406 | 0.110 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2014 | 11 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 380 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 391 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 353 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2015 | 136 | 0.110 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 266 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2004 | 3351 | 0.100 |
Why?
|
| Molecular Epidemiology | 2 | 2005 | 146 | 0.100 |
Why?
|
| Animals | 7 | 2023 | 34789 | 0.100 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 191 | 0.100 |
Why?
|
| Psychometrics | 3 | 2021 | 686 | 0.090 |
Why?
|
| Risk Factors | 4 | 2013 | 10941 | 0.090 |
Why?
|
| Bacillus anthracis | 2 | 2009 | 40 | 0.090 |
Why?
|
| Prevalence | 2 | 2011 | 2658 | 0.090 |
Why?
|
| Erythema Infectiosum | 1 | 2011 | 8 | 0.090 |
Why?
|
| China | 2 | 2024 | 290 | 0.090 |
Why?
|
| Mortality | 1 | 2013 | 264 | 0.090 |
Why?
|
| Schistosoma mansoni | 2 | 2023 | 24 | 0.090 |
Why?
|
| Parvovirus B19, Human | 1 | 2011 | 31 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 357 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 231 | 0.090 |
Why?
|
| Molecular Typing | 1 | 2011 | 34 | 0.090 |
Why?
|
| Ofloxacin | 1 | 2011 | 31 | 0.090 |
Why?
|
| Coinfection | 1 | 2013 | 189 | 0.090 |
Why?
|
| Aluminum Compounds | 1 | 2010 | 17 | 0.080 |
Why?
|
| alpha-Tocopherol | 2 | 2024 | 36 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2011 | 97 | 0.080 |
Why?
|
| Human Experimentation | 1 | 2010 | 35 | 0.080 |
Why?
|
| Exanthema | 1 | 2011 | 74 | 0.080 |
Why?
|
| Rural Population | 2 | 2024 | 239 | 0.080 |
Why?
|
| Phosphates | 1 | 2010 | 114 | 0.080 |
Why?
|
| Antibody Formation | 2 | 2025 | 274 | 0.080 |
Why?
|
| Antibodies, Protozoan | 1 | 2010 | 94 | 0.080 |
Why?
|
| Plasmodium falciparum | 1 | 2010 | 96 | 0.080 |
Why?
|
| Pregnancy | 4 | 2024 | 7543 | 0.080 |
Why?
|
| Drug Combinations | 2 | 2024 | 280 | 0.080 |
Why?
|
| Influenza A virus | 1 | 2010 | 152 | 0.080 |
Why?
|
| Vaccines, DNA | 1 | 2009 | 48 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17391 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 3011 | 0.080 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 216 | 0.070 |
Why?
|
| Logistic Models | 2 | 2005 | 1839 | 0.070 |
Why?
|
| Drug Administration Schedule | 3 | 2021 | 749 | 0.070 |
Why?
|
| HIV-1 | 1 | 2012 | 474 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3830 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 2140 | 0.070 |
Why?
|
| Europe | 1 | 2008 | 372 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 309 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2009 | 534 | 0.060 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 1 | 2006 | 12 | 0.060 |
Why?
|
| Tenofovir | 1 | 2006 | 23 | 0.060 |
Why?
|
| Research | 1 | 2008 | 265 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3770 | 0.060 |
Why?
|
| Neutralization Tests | 2 | 2017 | 236 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 1347 | 0.060 |
Why?
|
| Neuropsychological Tests | 2 | 2020 | 989 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2011 | 930 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 1799 | 0.060 |
Why?
|
| Cities | 1 | 2004 | 49 | 0.050 |
Why?
|
| Urban Health | 1 | 2004 | 78 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2004 | 78 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2023 | 12 | 0.050 |
Why?
|
| Carrier State | 1 | 2004 | 77 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 2 | 2000 | 197 | 0.050 |
Why?
|
| Vaccines, Combined | 1 | 2023 | 39 | 0.050 |
Why?
|
| Probability | 1 | 2004 | 322 | 0.050 |
Why?
|
| Aluminum Hydroxide | 1 | 2023 | 39 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2023 | 130 | 0.050 |
Why?
|
| Brazil | 1 | 2023 | 140 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 241 | 0.050 |
Why?
|
| Reference Values | 1 | 2004 | 704 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2024 | 306 | 0.050 |
Why?
|
| Protozoan Vaccines | 1 | 2023 | 96 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 294 | 0.050 |
Why?
|
| Bacterial Toxins | 2 | 2016 | 176 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1439 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 144 | 0.050 |
Why?
|
| Cation Transport Proteins | 1 | 2002 | 100 | 0.050 |
Why?
|
| Time Factors | 1 | 2012 | 6443 | 0.040 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2021 | 25 | 0.040 |
Why?
|
| Seasons | 1 | 2023 | 327 | 0.040 |
Why?
|
| Antigens, Bacterial | 2 | 2016 | 323 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2022 | 274 | 0.040 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 27 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 902 | 0.040 |
Why?
|
| Ethambutol | 1 | 2000 | 7 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1548 | 0.040 |
Why?
|
| Translations | 1 | 2020 | 18 | 0.040 |
Why?
|
| Recurrence | 1 | 2004 | 1468 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 93 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2024 | 8542 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 329 | 0.040 |
Why?
|
| HIV Seropositivity | 1 | 2000 | 128 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 52 | 0.040 |
Why?
|
| Age Distribution | 1 | 2000 | 438 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2000 | 430 | 0.040 |
Why?
|
| Translating | 1 | 2019 | 30 | 0.040 |
Why?
|
| Rural Health | 1 | 2019 | 44 | 0.040 |
Why?
|
| Child Language | 1 | 2019 | 33 | 0.040 |
Why?
|
| Culturally Competent Care | 1 | 2019 | 51 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 569 | 0.040 |
Why?
|
| Semen | 1 | 2019 | 81 | 0.040 |
Why?
|
| Antigens, Helminth | 1 | 2019 | 187 | 0.040 |
Why?
|
| Saliva | 1 | 2019 | 134 | 0.040 |
Why?
|
| Mothers | 1 | 2021 | 371 | 0.030 |
Why?
|
| Agglutination Tests | 1 | 2017 | 8 | 0.030 |
Why?
|
| Seroconversion | 1 | 2017 | 15 | 0.030 |
Why?
|
| Serogroup | 1 | 2017 | 63 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 504 | 0.030 |
Why?
|
| Equivalence Trials as Topic | 1 | 2017 | 24 | 0.030 |
Why?
|
| Viral Plaque Assay | 1 | 2017 | 42 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1179 | 0.030 |
Why?
|
| Vagina | 1 | 2019 | 204 | 0.030 |
Why?
|
| Baculoviridae | 1 | 2017 | 60 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2006 | 3760 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2017 | 107 | 0.030 |
Why?
|
| Emulsions | 1 | 2017 | 70 | 0.030 |
Why?
|
| Milk, Human | 1 | 2019 | 308 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1672 | 0.030 |
Why?
|
| Hemagglutination, Viral | 1 | 2015 | 10 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1057 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2015 | 51 | 0.030 |
Why?
|
| Immunization | 1 | 2017 | 312 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2004 | 3736 | 0.030 |
Why?
|
| Emigrants and Immigrants | 1 | 2015 | 158 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 1743 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2015 | 232 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 276 | 0.020 |
Why?
|
| Hospitalization | 1 | 2020 | 1898 | 0.020 |
Why?
|
| Pharynx | 1 | 2011 | 66 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 3991 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 540 | 0.020 |
Why?
|
| Nose | 1 | 2011 | 102 | 0.020 |
Why?
|
| Capsid Proteins | 1 | 2011 | 194 | 0.020 |
Why?
|
| New York | 1 | 2009 | 72 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2009 | 88 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 152 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 2913 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 673 | 0.020 |
Why?
|
| Safety | 1 | 2006 | 216 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 18461 | 0.010 |
Why?
|
| Dinucleotide Repeats | 1 | 2002 | 6 | 0.010 |
Why?
|
| Carbohydrate Dehydrogenases | 1 | 2000 | 3 | 0.010 |
Why?
|
| Pentosyltransferases | 1 | 2000 | 20 | 0.010 |
Why?
|
| Operon | 1 | 2000 | 48 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2002 | 413 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2000 | 824 | 0.010 |
Why?
|